{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:03:57Z","timestamp":1790687037271,"version":"4.1.0"},"reference-count":75,"publisher":"European Respiratory Society (ERS)","issue":"153","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2019,9,9]]},"published-print":{"date-parts":[[2019,9,30]]},"abstract":"<jats:p>New drugs and shorter treatments for drug-resistant tuberculosis (DR-TB) have become available in recent years and active pharmacovigilance (PV) is recommended by the World Health Organization (WHO) at least during the early phases of implementation, with active drug safety monitoring and management (aDSM) proposed for this. We conducted a literature review of papers reporting on aDSM. Up to 18 April, 2019, results have only been published from one national aDSM programme. Because aDSM is being introduced in many low- and middle-income countries, we also report experiences in introducing it into DR-TB treatment programmes, targeting the reporting of a restricted set of adverse events (AEs) as per WHO-recommended aDSM principles for the period 2014\u20132017. Early beneficial effects of active PV for TB patients include increased awareness about the occurrence, detection and management of AEs during TB treatment, and the increase of spontaneous reporting in some countries. However, because PV capacity is low in most countries and collaboration between national TB programmes and national PV centres remains weak, parallel and coordinated co-development of the capacities of both TB programmes and PV centres is needed.<\/jats:p>","DOI":"10.1183\/16000617.0115-2018","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T17:55:13Z","timestamp":1570816513000},"page":"180115","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences"],"prefix":"10.1183","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2071-3038","authenticated-orcid":false,"given":"Edine","family":"Tiemersma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"van den Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunta","family":"Dravniece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Wares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohannes","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusie","family":"Permata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endang","family":"Lukitosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-9269","authenticated-orcid":false,"given":"Mamel","family":"Quelapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Thu","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khay Mar","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Thanh","family":"Thuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-6716","authenticated-orcid":false,"given":"Vu Dinh","family":"Hoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merkinai","family":"Sulaimanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadat","family":"Sagyndikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mavluda","family":"Makhmudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alijon","family":"Soliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-9598","authenticated-orcid":false,"given":"Michael","family":"Kimerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"2024102403400482000_28.153.180115.1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0100"},{"key":"2024102403400482000_28.153.180115.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"2024102403400482000_28.153.180115.3","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0535"},{"key":"2024102403400482000_28.153.180115.4","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0075"},{"key":"2024102403400482000_28.153.180115.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00061-2017"},{"key":"2024102403400482000_28.153.180115.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"2024102403400482000_28.153.180115.7","unstructured":"World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-resistant Tuberculosis. Interim Policy Guidance . Geneva, World Health Organization, 2013."},{"key":"2024102403400482000_28.153.180115.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00125812"},{"key":"2024102403400482000_28.153.180115.9","unstructured":"World Health Organization. The Use of Delamanid in the Treatment of Multidrug-resistant Tuberculosis. Interim Policy Guidance . Geneva, World Health Organization, 2014."},{"key":"2024102403400482000_28.153.180115.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00724-2015"},{"key":"2024102403400482000_28.153.180115.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00387-2017"},{"key":"2024102403400482000_28.153.180115.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01799-2016"},{"key":"2024102403400482000_28.153.180115.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu786"},{"key":"2024102403400482000_28.153.180115.14","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0944"},{"key":"2024102403400482000_28.153.180115.15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024102403400482000_28.153.180115.16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5588\/ijtld.17.0840","article-title":"Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia","volume":"22","author":"Hewison","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403400482000_28.153.180115.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01528-2018"},{"key":"2024102403400482000_28.153.180115.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00544-2018"},{"key":"2024102403400482000_28.153.180115.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01699-2016"},{"key":"2024102403400482000_28.153.180115.20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.resinv.2019.01.001","article-title":"Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: an interim analysis of an open-label, phase 2 study","volume":"57","author":"Tsuyuguchi","year":"2019","journal-title":"Respir Investig"},{"key":"2024102403400482000_28.153.180115.21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3201\/eid2310.170303","article-title":"Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis","volume":"23","author":"Achar","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2024102403400482000_28.153.180115.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02550-2017"},{"key":"2024102403400482000_28.153.180115.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01154-2018"},{"key":"2024102403400482000_28.153.180115.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01462-2017"},{"key":"2024102403400482000_28.153.180115.25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"Von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102403400482000_28.153.180115.26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s12013-013-9589-5","article-title":"Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China","volume":"67","author":"Zhang","year":"2013","journal-title":"Cell Biochem Biophys"},{"key":"2024102403400482000_28.153.180115.27","unstructured":"World Health Organization. WHO Position Statement on the Use of Delamanid for Multi-Drug Resistant Tuberculosis. Expedited Review of the Phase III Clinical Trial Data of Delamanid Added to an Optimised Background MDR-TB Regimen . Geneva, World Health Organization, 2018."},{"key":"2024102403400482000_28.153.180115.28","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3201\/eid2310.170468","article-title":"Six-month response to delamanid treatment in MDR TB patients","volume":"23","author":"Hewison","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2024102403400482000_28.153.180115.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01105-2017"},{"key":"2024102403400482000_28.153.180115.30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00017-2018"},{"key":"2024102403400482000_28.153.180115.31","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx373"},{"key":"2024102403400482000_28.153.180115.32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/17512433.2016.1208562","article-title":"An update on repurposed medications for the treatment of drug-resistant tuberculosis","volume":"9","author":"Mafukidze","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024102403400482000_28.153.180115.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811867"},{"key":"2024102403400482000_28.153.180115.34","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2015.03.10"},{"key":"2024102403400482000_28.153.180115.35","first-page":"CD012836","article-title":"Linezolid for drug-resistant pulmonary tuberculosis","volume":"3","author":"Singh","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102403400482000_28.153.180115.36","unstructured":"World Health Organization. The Importance of Pharmacovigilance - Safety Monitoring of Medicinal Products . Geneva, World Health Organization, 2002."},{"key":"2024102403400482000_28.153.180115.37","unstructured":"World Health Organization. A Practical Handbook on the Pharmacovigilance of Medicines Use in the Treatment of Tuberculosis . Geneva, World Health Organization, 2012."},{"key":"2024102403400482000_28.153.180115.38","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000433951.09030.5a"},{"key":"2024102403400482000_28.153.180115.39","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/jac\/dkx107","article-title":"Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis","volume":"72","author":"Schnippel","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024102403400482000_28.153.180115.40","first-page":"275","article-title":"Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004","volume":"14","author":"Bloss","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403400482000_28.153.180115.41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4236\/jtr.2015.32004","article-title":"Adverse drug reactions in management of multi drug resistant tuberculosis, in tertiary chest institute","volume":"3","author":"Akshata","year":"2015","journal-title":"J Tuberc Res"},{"key":"2024102403400482000_28.153.180115.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61204-0"},{"key":"2024102403400482000_28.153.180115.43","unstructured":"Strengthening Pharmaceutical Systems (SPS) Program. Safety of Medicines in Sub-Saharan Africa: Assessment of Pharmacovigilance Systems and their Performance. Submitted to the US Agency for International Development by the SPS Program . Arlington, VA, Management Sciences for Health, 2011."},{"key":"2024102403400482000_28.153.180115.44","unstructured":"World Health Organization. Active TB Drug-Safety Monitoring and Management (aDSM). Framework for Implementation . WHO\/HTM\/TB\/2015.28. Geneva, World Health Organization, 2015."},{"key":"2024102403400482000_28.153.180115.45","unstructured":"World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis . WHO\/HTM\/TB\/2006.361. Geneva, World Health Organization, 2006."},{"key":"2024102403400482000_28.153.180115.46","unstructured":"Maher D , Raviglione MC . Why is a recording and reporting system needed, and what system is recommended? In: Frieden TR , ed. Toman's Tuberculosis . 2nd Edn. Geneva, World Health Organization, 2004; pp. 270\u2013273."},{"key":"2024102403400482000_28.153.180115.47","unstructured":"TBCARE-1. International Standards For Tuberculosis Care . 3rd Edn. The Hague, TBCARE-1, 2014."},{"key":"2024102403400482000_28.153.180115.48","unstructured":"World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis . WHO\/HTM\/TB\/2014.11. Geneva, World Health Organization, 2014."},{"key":"2024102403400482000_28.153.180115.49","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-012-0014-6"},{"key":"2024102403400482000_28.153.180115.50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00705-2016"},{"key":"2024102403400482000_28.153.180115.51","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu600"},{"key":"2024102403400482000_28.153.180115.52","unstructured":"World Health Organization. Global Tuberculosis Report 2018 . WHO\/CDS\/TB\/2018.20. Geneva, World Health Organization, 2018."},{"key":"2024102403400482000_28.153.180115.53","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4103\/0976-500X.99417","article-title":"Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form","volume":"3","author":"Singh","year":"2012","journal-title":"J Pharmacol Pharmacother"},{"key":"2024102403400482000_28.153.180115.54","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"2024102403400482000_28.153.180115.55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","article-title":"Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase\u00ae","volume":"39","author":"Ampadu","year":"2016","journal-title":"Drug Saf"},{"key":"2024102403400482000_28.153.180115.56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/17512433.2015.1053391","article-title":"Pharmacovigilance in resource-limited countries","volume":"8","author":"Olsson","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024102403400482000_28.153.180115.57","unstructured":"Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries. Submitted to the US Agency for International Development by SIAPS . Arlington, VA, Management Sciences for Health, 2013."},{"key":"2024102403400482000_28.153.180115.58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12992-018-0431-0","article-title":"Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences","volume":"14","author":"Ampadu","year":"2018","journal-title":"Global Health"},{"key":"2024102403400482000_28.153.180115.59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.4125","article-title":"Differences in VigiBase\u00ae reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment","volume":"26","author":"Sagwa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024102403400482000_28.153.180115.60","doi-asserted-by":"crossref","first-page":"e0120161","DOI":"10.1371\/journal.pone.0120161","article-title":"Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria","volume":"10","author":"Avong","year":"2015","journal-title":"PLoS One"},{"key":"2024102403400482000_28.153.180115.61","doi-asserted-by":"crossref","first-page":"e00297","DOI":"10.1002\/prp2.297","article-title":"Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016","volume":"5","author":"Oreagba","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"2024102403400482000_28.153.180115.62","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01643-2017"},{"key":"2024102403400482000_28.153.180115.63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1590\/s1806-37562018000000279","article-title":"Global TB Network: working together to eliminate tuberculosis","volume":"44","author":"Silva","year":"2018","journal-title":"J Bras Pneumol"},{"key":"2024102403400482000_28.153.180115.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.03.036"},{"issue":"Suppl. 60","key":"2024102403400482000_28.153.180115.65","first-page":"PA2682","article-title":"Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus \u2013 2014\u20132016","volume":"48","author":"Skrahina","year":"2016","journal-title":"Eur Respir J"},{"issue":"Suppl. 1","key":"2024102403400482000_28.153.180115.66","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijmyco.2016.11.014","article-title":"Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience","volume":"5","author":"Skrahina","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"2024102403400482000_28.153.180115.67","doi-asserted-by":"crossref","unstructured":"Bastard M , Molfino L , Mutaquiha C , et al. Treatment outcomes of patients switching from an injectable drug to bedaquiline during short standardized MDR-TB treatment in Mozambique. Clin Infect Dis 2019; https:\/\/doi.org\/10.1093\/cid\/ciz196","DOI":"10.1093\/cid\/ciz196"},{"key":"2024102403400482000_28.153.180115.68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00311-2017"},{"key":"2024102403400482000_28.153.180115.69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijtb.2019.02.009","article-title":"Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India","volume":"66","author":"Sarin","year":"2019","journal-title":"Indian J Tuberc"},{"key":"2024102403400482000_28.153.180115.70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijtb.2019.02.006","article-title":"Early efficacy and safety of bedaquiline and delamanid given together in a \u201csalvage regimen\u201d for treatment of drug-resistant tuberculosis","volume":"66","author":"Sarin","year":"2019","journal-title":"Indian J Tuberc"},{"key":"2024102403400482000_28.153.180115.71","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5588\/ijtld.15.0318","article-title":"Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment","volume":"20","author":"Kelly","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403400482000_28.153.180115.72","doi-asserted-by":"crossref","first-page":"e0200810","DOI":"10.1371\/journal.pone.0200810","article-title":"Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV\/AIDS, tuberculosis and malaria: a prospective cohort study","volume":"13","author":"Avong","year":"2018","journal-title":"PloS One"},{"key":"2024102403400482000_28.153.180115.73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5588\/ijtld.16.0493","article-title":"Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries","volume":"21","author":"Guglielmetti","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403400482000_28.153.180115.74","doi-asserted-by":"crossref","first-page":"e151430","DOI":"10.3201\/eid2203.151430","article-title":"Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis","volume":"22","author":"Furin","year":"2016","journal-title":"Emerging Infect Dis"},{"key":"2024102403400482000_28.153.180115.75","unstructured":"Challenge TB . Generic Programmatic and Clinical Guide for Introduction of New Drugs and Shorter Regimens for Treatment of M\/XDR-TB. Version 20 . The Hague, KNCV Tuberculosis Foundation, 2017."}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0115-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:01:14Z","timestamp":1740373274000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0115-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":75,"journal-issue":{"issue":"153","published-online":{"date-parts":[[2019,10,11]]},"published-print":{"date-parts":[[2019,9,30]]}},"alternative-id":["10.1183\/16000617.0115-2018"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0115-2018","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]}}}